Cambridge Bioscience is delighted to announce a new strategic distribution partnership with Immuno-Biological Laboratories Co., Ltd. (IBL), following our recent acquisition of Stratech Scientific. This partnership expands access to IBL’s innovative portfolio of antibodies, ELISA kits, immunological research reagents and specialised biomarker research solutions for life science and translational researchers across the UK and Ireland.
The partnership will provide scientists with streamlined access to IBL’s extensive range of products and services, including monoclonal and polyclonal antibodies, ELISA assay kits, customised antibody development services and specialised research tools supporting applications in immunology, biomarker discovery, neurodegenerative disease research, kidney disease, metabolic disorders and healthy ageing research. Researchers will also benefit from access to LipoSEARCH®, IBL’s advanced lipid profiling and analysis service.
IBL is a Japan-based developer and manufacturer of ISO 13485-certified life science and diagnostic research solutions. The company is recognised for its expertise in antibody development and disease biomarker research, with a strong focus on ageing-related conditions, Alzheimer's disease and other neurodegenerative disorders, inflammatory diseases, kidney diseases and metabolic disorders. IBL serves pharmaceutical companies, diagnostic manufacturers, universities, hospitals and biomedical research institutes worldwide.
Through this partnership, Cambridge Bioscience will provide local technical support, product expertise and customer service, ensuring researchers across the UK and Ireland can fully leverage IBL’s trusted portfolio of high-quality reagents, biomarker assays and custom antibody development capabilities to accelerate scientific discovery and translational research.
This collaboration further strengthens Cambridge Bioscience’s commitment to supporting the UK and Ireland life science community with high-quality tools and technologies that accelerate research, innovation and discovery.
Learn more about IBL’s portfolio or contact our IBL specialists.